Related Experiment Video

Updated: May 17, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

ETV6-NTRK3 as a therapeutic target of small molecule inhibitor PKC412

Hoang Thanh Chi1, Bui Thi Kim Ly, Yasuhiko Kano

  • 1Department of Medical Genome Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo 108-8639, Japan. kk086406@mgs.k.u-tokyo.ac.jp

Biochemical and Biophysical Research Communications
|November 8, 2012
PubMed

Insights

Midostaurin (PKC412) inhibits the ETV6-NTRK3 (EN) fusion gene, a driver in cancers like congenital fibrosarcoma. This drug suppresses downstream signaling, halting cancer cell growth and promoting cell death, offering a potential therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • The ETV6-NTRK3 (EN) fusion gene arises from the t(12;15)(p13;q25) translocation.
  • EN is implicated in congenital fibrosarcoma (CFS), congenital mesoblastic nephroma (CMN), secretory breast carcinoma (SBC), and acute myelogenous leukemia (AML).

Purpose of the Study:

  • To investigate the therapeutic potential of midostaurin (PKC412) against the EN fusion gene.
  • To elucidate the molecular mechanisms by which PKC412 affects EN-driven cellular processes.

Main Methods:

  • Utilized cell lines IMS-M2 and M0-91 harboring the EN fusion gene.
  • Employed Ba/F3 cells stably transfected with the EN fusion gene.
  • Assessed the inhibitory effects of PKC412 on EN activity and downstream signaling pathways.

Main Results:

  • PKC412 demonstrated potent inhibition of EN tyrosine kinase activity.
  • Inhibition of EN by PKC412 led to suppressed downstream signaling.
  • PKC412 treatment resulted in reduced cell proliferation and induced apoptosis in EN-positive cells.

Conclusions:

  • PKC412 (midostaurin) is identified as an effective inhibitor of the EN fusion gene.
  • The findings suggest PKC412 as a promising therapeutic agent for cancers driven by the EN fusion.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...